138505-14-3

Basic information

• Product Name: 2-(3,4-dimethoxyphenyl)propanoic acid
• CAS NO: 138505-14-3
• Molecular Weight: 210.23
• Mol File: 138505-14-3.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: 2-(3,4-dimethoxyphenyl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-dimethoxyphenyl)propanoic acid(138505-14-3)
• EPA Substance Registry System: 2-(3,4-dimethoxyphenyl)propanoic acid(138505-14-3)

Safety Data

• Hazardous Substances Data: 138505-14-3(Hazardous Substances Data)

Upstream product

• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 74-88-4 methyl iodide 
• 51698-53-4 2‐(3,4‐dimethoxyphenyl)propionitrile 
• 18066-68-7 ethyl 3,4-dimethoxyphenylacetate 
• 1835-04-7 ethyl 3,4-dimethoxyphenyl ketone 
• 93-07-2 Veratric acid 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 6380-23-0 3,4-dimethoxystyrene 
• 124-38-9 carbon dioxide 
• 40181-00-8 2-(3,4-di-methoxyphenyl)propionaldehyde 
• 29207-02-1 methyl 2-(3,4-dimethoxyphenyl)propanoate 
• 15964-79-1 methyl (3,4-dimethoxyphenyl)acetate 
• 64-18-6 formic acid 

Downstream Products

• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 1386351-09-2 (S)-2-(3,4-dimethoxyphenyl)-N-((R)-2-hydroxy-1-phenylethyl)propanamide 
• 1386351-11-6 (R)-2-(3,4-dimethoxyphenyl)-N-((R)-2-hydroxy-1-phenylethyl)propanamide 
• 234089-49-7 (S)-(+)-2-(3,4-dimethoxyphenyl)propanoic acid 
• 1386351-16-1 (S)-2-(3,4-dimethoxyphenyl)propanoic acid 
• 1192280-95-7 (S)-2-(3,4-dimethoxyphenyl)propionaldehyde 
• 1386350-39-5 (S)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 
• 390815-40-4 (R)-2-(3,4-dimethoxyphenyl)propanoic acid 
• 1386351-20-7 C₁₁H₁₆O₃ 
• 1386351-18-3 (R)-2-(3,4-dimethoxyphenyl)propionaldehyde 
• 1386350-40-8 (R)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 
• 55174-61-3 2-(3,4-dimethoxyphenyl)propan-1-amine 

Relevant articles and documents

Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design

Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disease whose pathogenesis cannot be defined by one single element but consists of various factors; thus, there is a call for alternative approaches to tackle the multifaceted aspects of AD. Among the potential alternative targets, we aim to focus on glutaminyl cyclase (QC), which reduces the toxic pyroform of β-amyloid in the brains of AD patients. On the basis of a putative active conformation of the prototype inhibitor 1, a series of N-substituted thiourea, urea, and α-substituted amide derivatives were developed. The structure-activity relationship analyses indicated that conformationally restrained inhibitors demonstrated much improved QC inhibition in vitro compared to nonrestricted analogues, and several selected compounds demonstrated desirable therapeutic activity in an AD mouse model. The conformational analysis of a representative inhibitor indicated that the inhibitor appeared to maintain the Z-E conformation at the active site, as it is critical for its potent activity.

Synthesis of Bicyclo[n.1.0]alkanes by a Cobalt-Catalyzed Multiple C(sp3)?H Activation Strategy

A cobalt-catalyzed dual C(sp3)?H activation strategy has been developed and it provides a novel strategy for the synthesis of bicyclo[4.1.0]heptanes and bicyclo[3.1.0]hexanes. A key to the success of this reaction is the conformation-induced methylene C(sp3)?H activation of the resulting cobaltabicyclo[4.n.1] intermediate. In addition, the synthesis of bicyclo[3.1.0]hexane from pivalamide, by a triple C(sp3)?H activation, has also been demonstrated.

Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.